A Clinical Trial to Investigate the Acute Effect of Bragg Apple Cider Vinegar Supplement on Blood… (NCT07100977) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
A Clinical Trial to Investigate the Acute Effect of Bragg Apple Cider Vinegar Supplement on Blood Glucose Control in a Healthy Adult Population
Canada24 participantsStarted 2026-01
Plain-language summary
The goal of this clinical trial is to evaluate the efficacy of a Bragg ACV supplement on postprandial glucose excursion compared to a placebo following a standardized acute carbohydrate load.
Participants will be asked to consume an apple cider vinegar supplement 10 minutes prior to a standardized meal.
Who can participate
Age range20 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Males and females 20 - 65 years of age, inclusive
✓. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening
✓. Subjects with elevated fasting glucose \> 5.6 mmol/L (\> 100 mg/dL) and \< 7.0 mmol/L (\< 126 mg/dL) and/or elevated HbA1c (6.0-6.4%) and two or more of the other following markers associated with metabolic syndrome at screening:
✓. Abdominal obesity: waist circumference \> 102 cm (40 inches) in men and \> 88 cm (35 inches) in women
✓. Low HDL-C: \< 40 mg/dL (1.03 mmol/L) in men and \< 50 mg/dL (1.29 mmol/L) in women
✓. Stable body weight defined as a \<5% change in body weight in the three months prior to baseline, as assessed by the Qualified Investigator (QI)
Exclusion criteria
✕. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
✕. Allergy, sensitivity or intolerance, preventing consumption of investigational product, placebo, or standardized meal
✕
What they're measuring
1
The difference in the incremental area under the curve (iAUC)(0 - 120 min) for venous blood glucose between Bragg ACV supplement and placebo following an acute carbohydrate load.
✕. Current use of prescribed and/or OTC medications, supplements, and/or consumption of food/drinks that may impact the glucose metabolism or efficacy of the investigational product (Sections 7.3.1 and 7.3.2)
✕. Unstable metabolic disease or chronic diseases as assessed by the QI
✕. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI
✕. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI